Earlier studies on the association between celiac disease (CD) and psoriasis show contradictory results. The purpose of this study was to assess the risk of psoriasis in patients with biopsy-verified CD. Through 28 pathology departments in Sweden, we identified individuals with CD diagnosed between 1969 and 2008 (Marsh 3: villous atrophy; n ¼ 28,958 unique individuals). We then used Cox regression to compare individuals with CD with 143,910 sex-and age-matched controls regarding their risk of psoriasis. CD was a risk factor for future psoriasis (hazard ratio (HR) ¼ 1.72; 95% confidence interval (CI) ¼ 1.54-1.92; during follow-up, 401 individuals with CD and 1,139 controls had a diagnosis of psoriasis). The absolute risk of future psoriasis in patients with CD was 135/100,000 person-years (excess risk ¼ 57/100,000). In all, 42% of all psoriasis in patients with CD could be attributed to the underlying CD. Moreover, in children we saw a positive association between CD and psoriasis (HR ¼ 2.05; 95% CI ¼ 1.62-2.60). The association between CD and psoriasis seems to be independent of a temporal relationship, as we also found a positive association between CD and psoriasis before CD diagnosis (odds ratio ¼ 1.91; 95% CI ¼ 1.58-2.31). In conclusion, individuals with CD were at increased risk of psoriasis both before and after CD diagnosis.
INTRODUCTION
Celiac disease (CD) is an immune-mediated disease that occurs in B1% of the western population. This disease is triggered by gluten exposure in genetically sensitive individuals. Earlier research suggests that CD is associated with a number of autoimmune diseases (Collin et al., 2002; Ludvigsson et al., 2006; Elfstrom et al., 2007 Elfstrom et al., , 2008 Neuhausen et al., 2008) .
Psoriasis is a chronic autoimmune skin disease. Common symptoms include red scaly patches on the skin. Some patients have affected nails and joints (psoriatic arthritis).
Earlier research has suggested a link between CD and psoriasis (Ojetti et al., 2003; Birkenfeld et al., 2009; Tursi et al., 2010) , but such an association has also been questioned (Collin and Reunala, 2003) and several papers suffer from limitations including small numbers of patients with CD (Tursi et al., 2010) and lack of controls (Tursi et al., 2010) . A recent paper also found a higher prevalence of CD-associated antibodies in patients with psoriasis (Singh et al., 2010 ; although data are conflicting; Kia et al., 2007) , and some patients with psoriasis and antigliadin antibodies will improve on a gluten-free diet despite the absence of villous atrophy (VA) on biopsy (Michaelsson et al., 2000; Addolorato et al., 2003) . It may also be that disease activity in psoriasis correlates with levels of CD-associated antibodies (Lindqvist et al., 2002; Woo et al., 2004) . In a recent large population-based case-control study, Birkenfeld et al. (2009) reported that patients with psoriasis had more CD than matched controls, but the prevalence of CD in that study was only 0.11%, whereas it is generally agreed that CD occurs in about 1% of the normal population (Dube et al., 2005) .
The main objective of this study was to examine the prevalence of psoriasis in a nationwide population-based sample of patients with biopsy-verified CD.
RESULTS

Background data
Some 60% of participants were female (Table 1) , and the median age at study entry was 30 years. Median follow-up was 9 years.
The median age at first diagnosis of psoriasis was 52 years in individuals with CD and 55 years in controls. The median duration from study entry until first recorded diagnosis of psoriasis was 7 years in both those with CD and in their controls.
CD and risk of psoriasis
During the study period, 401 individuals with CD and 1,139 controls developed psoriasis. This corresponded to a hazard ratio (HR) of 1.72 (95% confidence interval (CI) ¼ 1.54-1.92; Table 2 ). The absolute risk of future psoriasis in patients with CD was 135/100,000 person-years, with an excess risk of 57/100,000. Some 42% of all psoriasis in patients with CD could be attributed to the underlying CD (Table 2) .
The HR for psoriasis remained around 1.7 also when we excluded the first year of follow-up (HR ¼ 1.71; 95% CI ¼ 1.52-1.92). Even 5 years after CD diagnosis did we see a more than 60% increased risk for psoriasis in patients with CD (Table 2) .
Adjustment for type 1 diabetes, rheumatoid arthritis, and autoimmune thyroid disease did not affect the risk estimates (adjusted HR ¼ 1.70; 95% CI ¼ 1.52-1.91). Neither did adjustment for country of birth (adjusted HR ¼ 1.70; 95% CI ¼ 1.52-1.90) nor education (adjusted HR ¼ 1.72; 95% CI ¼ 1.54-1.93) influence the risk estimates. We found similar risk estimates in men and women (Table 3 ). Interaction tests revealed that the risk of psoriasis in CD did not differ significantly according to sex (P ¼ 0.238) or according to age at biopsy (P ¼ 0.241). Children (diagnosed o20 years of age) with CD were at a statistically significantly increased risk of later psoriasis (HR ¼ 2.05; 95% CI ¼ 1.62-2.60; Table 3 ). Also when we excluded individuals with any skin disease (psoriasis þ other skin disease), CD was still associated with future psoriasis (HR ¼ 1.69; 95% CI ¼ 1.50-1.91).
Psoriasis confirmed by psoriatic medication
Individuals with CD were at a 2-fold increased risk of having a diagnosis of psoriasis confirmed by a record of psoriatic medication. However, because of few positive events, this association was not statistically significant (four individuals with CD versus nine controls fulfilled our criteria; HR ¼ 2.06; 95% CI ¼ 0.63-6.70; P ¼ 0.231).
Comparison with other individuals undergoing small intestinal biopsy
Compared with individuals undergoing small intestinal biopsy but not having VA, individuals with CD were at no increased risk of psoriasis (compared with inflammation (Marsh 1-2): HR ¼ 0.96; 95% CI ¼ 0.71-1.30 and compared with those with normal mucosa (Marsh 0) but positive CD serology: HR ¼ 0.99; 95% CI ¼ 0.83-1.18).
Previous psoriasis and risk of later CD
Out of 29,096 individuals with CD, 137 (0.47%) had a previous diagnosis of psoriasis versus 341/144,522 (0.23%). Hence, we found a positive association between CD and psoriasis also before CD diagnosis. A previous psoriasis diagnosis increased the risk for future CD (odds ratio ¼ 1.91; 95% CI ¼ 1.58-2.31). 
DISCUSSION
To our knowledge, this is the largest study to date on CD and psoriasis. It was based on almost 29,000 individuals with biopsy-verified CD identified from 28 Swedish pathology departments. Psoriasis was defined according to outpatient or inpatient International Classification of Disease (ICD) codes. Earlier validation has shown high validity for most chronic conditions in the Swedish national patient register (Ragnarson Tennvall et al., 2000; Hultgren et al., 2001; Smith et al., 2009) . Almost all Swedish health care is publicly funded, guaranteeing a virtually 100% complete follow-up through linkage with the unique personal identity number.
Comparison with earlier literature
As opposed to the recent Israeli study by Birkenfeld et al. (2009;  with an odds ratio of 2.73), our risk estimates were consistently below two. One explanation for our lower risk estimates deals with our ascertaining CD through pathology databases. Ascertaining CD through pathology databases has previously yielded lower risk estimates than similar studies using the inpatient registers to identify CD (compare, e.g., relative risks of death in CD: Ludvigsson et al. (2009c) : 1.39 with Peters et al. (2003) : 2.0. Another, perhaps more likely, explanation of our lower risk estimates is the rarity of diagnosed CD in Israel. It is possible that most patients in that study suffered from (severe) symptomatic CD (0.11% of controls had CD (Birkenfeld et al., 2009 ), whereas 29,000 patients with CD in the current study equal around 0.3% of the Swedish population).
Although we did not screen the entire Swedish population for CD, our data indicate a 2-fold increased risk of CD in patients with previous psoriasis. This is consistent with recent data from Montesu et al. (2011) . In their study, 2% of psoriasis patients had CD (as compared with expected 1% (Dube et al., 2005) ), although none of their controls showed a positive CD serology (Montesu et al., 2011) . Woo et al. (2004) in a series of 130 psoriatic patients found 3 (2.3%) patients with VA, and also reported that positive CD serology correlated with increased disease activity in psoriasis. An Italian study reported that 4/92 (4.3%) patients with psoriasis versus 0/90 controls had CD (Ojetti et al., 2003) ; and a Swedish study that 5/114 (4.4%) individuals with psoriatic arthritis had CD (the Swedish study used no controls; Lindqvist et al., 2002) . Meanwhile, an Iranian study failed to show an increased prevalence of CD in 328 patients with psoriasis (Zamani et al., 2010) .
Our study was based on histopathological evidence of CD, and is therefore difficult to compare with studies on psoriasis and CD serology (Michaelsson et al., 1993; Kia et al., 2007; Damasiewicz-Bodzek and Wielkoszynski, 2008; Sultan et al., 2010) . Studies on CD serology in psoriatic patients have been both positive (Michaelsson et al., 1993; Damasiewicz-Bodzek and Wielkoszynski, 2008) and negative (Kia et al., 2007; Sultan et al., 2010) . Heterogeneity can probably be explained through the low positive predictive value of CD serology (Hopper et al., 2007) , especially antigliadin antibodies (43% in the paper by Hadithi et al. (2007) ).
Mechanisms
Several mechanisms might explain the positive association between CD and psoriasis described in this study. First, malabsorption in CD, both before and after diagnosis, increases the risk of vitamin D deficiency (Bode et al., 1991) and besides the gluten-free diet is often low in vitamin D (Kupper, 2005) . Vitamin D deficiency predisposes to psoriasis, and exposure to sun light as well a administration of vitamin D analog creams have a beneficial effect on psoriasis (Lehmann, 2009) . Second, in patients with CD (before and after diagnosis), exposure to gliadin will trigger a CD4 þ T-cell response and a cascade of proinflammatory cyotkines such as IFN-g (Nilsen et al., 1998) . The increased number of T cells in the blood may affect also the dermis and epidermis, thereby stimulating the development of psoriasis (Monteleone et al., 2010) . The psoriatic plaque is characterized by a marked infiltration of activated CD4 þ and CD8 þ T cells. CD4 þ T cells infiltrate mainly the dermis, whereas CD8 þ T cells are present in the epidermis (Nestle et al., 2009) . Third, shared genetic factors could have a role. Liu et al. (2008) first described a psoriatic locus on chromosome 4q27 that harbors both IL-2 and IL-21. This locus (IL2/21) has previously been linked to CD (van Heel et al., 2007; Adamovic et al., 2008) . A fourth potential mechanism regards the increase in intestinal permeability (Abenavoli et al., 2009 ) seen in patients with psoriasis (Humbert et al., 1991) . Affected intestinal permeability is a hallmark of CD. Still, further studies are needed to explore the underlying mechanism for the positive association between CD and psoriasis, as our study lacks individual-based immunological and genetic data.
Strengths and limitations
This study was based on almost 29,000 patients with CD. The large numbers allowed for important subanalyses and, for instance, we were able to examine the relationship between CD and psoriasis in children. Although we cannot rule out that our HR is slightly inflated by ascertainment bias, such bias is unlikely to fully explain the positive association seen in this study, as the risk increase remained more than 5 years after CD diagnosis. VA has been the gold standard for CD diagnosis in Sweden since the 1970s (Cavell et al., 1992; Stenhammar et al., 2006) , and in a recent survey, 96% of adult gastroenterologists and 100% of pediatricians perform a small intestinal biopsy in at least 90% of patients with suspected CD before assigning a diagnosis of CD (Ludvigsson et al., 2009b) . When we reviewed 114 randomly selected patient charts from patients with VA, 108 (95%) had CD. Moreover, when we manually reviewed more than 1,500 biopsy reports, we found that other diagnoses than CD seldom explain VA (0.3% of those with VA had inflammatory bowel disease and 0.2% suffered from Helicobacter pylori; Ludvigsson et al., 2009b) . Although we did not require a positive CD serology for our CD diagnosis, 88% of validated individuals with VA and available serology data had positive CD serology at the time of biopsy (Ludvigsson et al., 2009b) . We would also like to underline our use of different reference groups. Compared with individuals with inflammation or normal mucosa but positive CD serology, those with CD were at no increased risk of psoriasis. This suggests that the risk increase for psoriasis may not require severe mucosal abnormalities but that microscopic inflammation including intraepithelial lymphocytosis may be sufficient. Moreover, we were able to link our data to the Swedish Prescribed Drug Register. Although that register covers only a short time span, the relative risk in that analysis (HR ¼ 2.06) indicates that the positive association seen in our main analysis is not a chance finding. However, the small number of individuals with medication registered in the Prescribed Drug Register meant that the association was not statistically significant.
This study also had some weaknesses. We were unable to measure the activity of psoriasis. We did not have access to smoking data. Smoking is, however, inversely related to CD (Snook et al., 1996;  if at all related (Ludvigsson et al., 2005) ), but positively associated with psoriasis (Naldi et al., 2005; Jankovic et al., 2009 ). Hence, confounding by smoking cannot explain the positive association between CD and psoriasis seen in this study. Neither did we have data on alcohol consumption. Alcohol consumption has been linked to psoriasis (Poikolainen et al., 1990) but not to CD (McMillan et al., 1998) . When Zingone et al. (2009) examined risk factors for psoriasis in patients with CD, they found that the risk of psoriasis was higher in patients with undiagnosed CD and a high body mass index, as opposed to those with normal body mass index. Unfortunately the current study did not have access to data on body mass index. Finally we had no data on dietary compliance and vitamin D status. This means that we were unable to estimate the importance of adhering to a gluten-free diet for the risk of psoriasis, and what role vitamin D status may have had for the development of psoriasis.
In conclusion, we found an increased risk of psoriasis in patients with CD. This risk increase was seen both before and after diagnosis of CD. It was seen in all age strata and remained more than 5 years after CD diagnosis.
MATERIALS AND METHODS
We linked nationwide biopsy data on CD with inpatient and outpatient data on psoriasis. Through Cox regression, we estimated HRs for psoriasis in the Swedish Patient Register and in a subanalysis also when the diagnosis of psoriasis was confirmed by a record of medication in the Swedish Prescribed Drug Register.
Data collection
Between October 2006 and February 2008, we collected computerized biopsy data from all Swedish pathology departments (n ¼ 28), with biopsies performed between 1969 and 2008. Data from biopsies included arrival date of biopsies, personal identity number (Ludvigsson et al., 2009d) , morphology, and topography (duodenum and jejunum).
We defined CD as having VA (Marsh 3) according to the Swedish SnoMed classification (for a translation of the SnoMed classification, please see the Supplementary Appendix online).
We did not request a positive CD serology for the diagnosis of CD, although earlier validation of a subset of randomly selected individuals with CD has shown that 88% had positive CD serology at time of biopsy (Ludvigsson et al., 2009b) . Of individuals with VA and available data, 2,268/3,374 (67.2%) had positive IgA tissue transglutaminase/endomysial, whereas 1,106 (32.8%) were positive for IgA Gliadin or IgG tissue transglutaminase/endomysial/gliadin. In the current study, 95% of individuals with VA (108/114) had CD according to patient charts (Ludvigsson et al., 2009b ) and 79% of individuals had gastrointestinal symptoms before biopsy.
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Controls
For each individual undergoing biopsy, Statistics Sweden selected up to five controls matched for age, sex, calendar period, and county from the Total Population Register. Controls were sampled from all Swedish residents who had no previous duodenal/ jejunal biopsy.
Secondary reference groups of individuals undergoing biopsy
For comparative reasons, we also collected biopsy data of patients with inflammation without VA (Marsh 1-2) and normal mucosa but positive CD serology (Marsh 0 with positive IgA/IgG for antigliadin, endomysial, or tissue transglutaminase) (Ludvigsson et al., 2009a) . These two cohorts were used as secondary reference groups. In the most commonly used Swedish histopathology classification (Committee for Quality and Standardization), inflammation is equal to intraepithelial inflammation. More information on the data collection method has been published in two validation papers (Ludvigsson et al., 2009a, b) .
Exclusions
After matching to (primary) controls, we excluded 174 individuals where the biopsy (VA, inflammation, or normal mucosa) could potentially have been from the ileum, those with no matched control, or those who lacked a serial number from Statistics Sweden (n ¼ 35). We excluded 247 controls because of data irregularities and an additional 921 controls who could not be matched. The remaining individuals are identical to those in our study on mortality in CD (Ludvigsson et al., 2009c) .
Additional exclusions are shown in Figure 1 . For the purpose of our initial analyses, we excluded anyone with a diagnosis of psoriasis before study entry (date of first biopsy). As each stratum (one individual with CD and his/her controls) was analyzed separately, a number of controls were excluded as their index individual with CD had been excluded.
The main analyses of this paper were based on 28,958 individuals with CD and 143,910 general population controls. The secondary reference groups consisted of 13,223 individuals with inflammation and 3,686 individuals with normal mucosa but positive CD serology.
Outcome
Our main outcome was a diagnosis of psoriasis defined according to relevant ICD codes (ICD-7 (1964 (ICD-7 ( -1968 , ICD-8 (1969 ICD-8 ( -1986 , ICD-9 (1987 ICD-9 ( -1996 and ICD-10 (1997-, code L40); Ji et al., 2009) in the Swedish Patient Register. This register contains both inpatient data (from 1964 and nationwide since 1987) and hospital outpatient data (since 2001 and nationwide from the start).
In a subanalysis, we examined the risk of having a diagnosis of psoriasis confirmed by a record of psoriatic medicine (including biological treatments) in the Swedish Prescribed Drug Register. This register was initiated in mid-2005 and contains outpatient data on medication according to relevant Anatomical Therapeutic Chemical Classification System codes (see Supplementary Appendix online). When we only included individuals with a follow-up until, at least, 1 July 2005 this subanalysis was based on 26,219 individuals with CD and 132,007 controls.
Statistics
Prospective analyses: CD and risk of later psoriasis. We used internal stratified Cox regression to estimate HRs for psoriasis. The internal stratification means that the index individual was only compared with his or her controls within the same stratum and then a summary risk estimate was calculated. The proportional hazards assumption was tested through plotting log-minus-log curves. Follow-up started on the date of the first biopsy with VA and the corresponding date in matched controls. Follow-up ended with psoriasis diagnosis, death, emigration, or on 31 December 2008, whichever happened first. Attributable risks (%) were calculated as (1-1/HR), and absolute risk as number of incident cases with psoriasis divided by years of follow-up.
In a priori subanalyses, we examined the risk of psoriasis by follow-up period, sex, age, and calendar year at CD diagnosis. Incidence rates were calculated as the number of first recorded psoriasis diagnoses per person-years at risk.
In a subanalysis, we also adjusted for type 1 diabetes mellitus, rheumatoid arthritis, autoimmune thyroid disease (see Supplementary Appendix online for ICD codes), level of education, and country of birth (Nordic country vs non-Nordic country on education were retrieved from Statistics Sweden and grouped according to seven pre-defined levels. In a post hoc analysis, we excluded all individuals with any skin disease before study entry (this analysis was based on 27,051 individuals with CD and 138,808 matched reference individuals). Finally, we examined the risk of psoriasis in individuals with CD compared with the risk in secondary reference groups undergoing small intestinal biopsy but not having VA.
Case-control study: previous psoriasis and risk of later CD. In a case-control study we used conditional logistic regression to examine the relationship between previous psoriasis and later CD. Moreover, in this analysis did we define psoriasis according to relevant ICD codes. We based this analysis on 29,096 individuals with CD and 144,522 controls matched for sex, age, calendar period, and county (Figure 1 ). We then looked at the number of individuals with a previous diagnosis of psoriasis.
We used SPSS 18.0 (Chicago, IL) to perform all analyses. Relative risks with 95% CIs that did not include 1 were regarded as statistically significant.
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